What is pleomorphic rhabdomyosarcoma?
Pleomorphic rhabdomyosarcoma (PRMS) is a rare, aggressive soft tissue sarcoma that develops in adults. It belongs to the rhabdomyosarcoma family, a group of cancers whose cells show features of skeletal muscle, the muscle we use to move. The word pleomorphic means “many shapes”: under the microscope, the tumour contains large, bizarre cells of varying size and shape.
Most rhabdomyosarcomas are childhood cancers, especially the embryonal and alveolar types. Pleomorphic rhabdomyosarcoma is different. It is the main form of rhabdomyosarcoma in adults, usually affecting people in middle and older age, and it behaves more like other high-grade adult sarcomas than like the childhood types (Hollowood and Fletcher, 1994).
PRMS usually appears as a deep, growing lump, most often in the thigh or leg, but it can arise in the trunk, abdomen and other sites. It tends to spread, especially to the lungs, and often returns after treatment.
Treatment is based on surgery with wide margins, usually combined with radiotherapy. Chemotherapy is used for advanced disease, but responses are often limited. Newer research has found that some of these tumours occur in people with Lynch syndrome and may respond to immunotherapy (Poumeaud et al., 2025).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | High-grade soft tissue sarcoma with skeletal muscle features |
| Who is affected | Adults; median age 54 in one series and 71.5 in another |
| Sex | More common in men |
| Usual site | Deep soft tissue of the lower limb; also trunk, abdomen and other sites |
| Main symptom | A growing, sometimes painful lump |
| Spread | Common, especially to the lungs |
| Main treatment | Wide surgical removal and radiotherapy |
| Chemotherapy | Used in advanced disease; responses often short |
| Outlook | Poor overall; better when the tumour is small and fully removed |
2. Types
Rhabdomyosarcoma subtypes
| Subtype | Usual age | Behaviour | Typical treatment |
|---|---|---|---|
| Embryonal | Children | Often responsive to chemotherapy | Paediatric chemotherapy, surgery, radiotherapy |
| Alveolar | Children and young adults | Aggressive; FOXO1 fusions | Paediatric protocols |
| Spindle cell/sclerosing | Children and adults | Variable | Depends on genetics |
| Pleomorphic | Older adults | Aggressive; poor response to chemotherapy | Adult sarcoma approach |
Variants of pleomorphic rhabdomyosarcoma
A study of 38 adult cases described three variants under the microscope (Furlong, Mentzel and Fanburg-Smith, 2001).
| Variant | Description | Cases |
|---|---|---|
| Classic | Sheets of large, atypical pleomorphic cells | 8 |
| Round cell | Clusters of large cells among smaller round cells | 13 |
| Spindle cell | Scattered large cells among atypical spindle-shaped cells | 17 |
All three behave as high-grade sarcomas.
How it differs from undifferentiated pleomorphic sarcoma
| Feature | Pleomorphic rhabdomyosarcoma | Undifferentiated pleomorphic sarcoma |
|---|---|---|
| Muscle markers | At least one skeletal muscle-specific marker positive | No specific line of differentiation |
| Outlook | Generally poorer | Variable |
| Treatment | Similar adult sarcoma principles | Similar adult sarcoma principles |
Why this tumour was once controversial
For several decades, pathologists debated whether pleomorphic rhabdomyosarcoma truly existed as a separate disease. In the past, many pleomorphic sarcomas were labelled as rhabdomyosarcoma; later, the diagnosis became unfashionable. Modern stains and electron microscopy showed that a genuine group of adult tumours has clear skeletal muscle features and a distinct, aggressive course (Hollowood and Fletcher, 1994). Today, the diagnosis is made only when muscle-specific markers confirm it.
3. Causes and risk factors
| Factor | Notes |
|---|---|
| Age | Mainly middle-aged and older adults |
| Male sex | In the Furlong series, 28 of 38 patients were men |
| Lynch syndrome | Inherited mismatch repair defect; pleomorphic sarcomas, including PRMS, are over-represented in these patients |
| Previous radiotherapy | A recognised risk factor for sarcomas in general |
| Lifestyle | No known link |
The link with Lynch syndrome
Lynch syndrome is an inherited condition that raises the risk of bowel, womb and other cancers. A French national study of 81 people with Lynch syndrome who developed sarcomas found that most of the soft tissue sarcomas had a pleomorphic component, and about a fifth of these were pleomorphic rhabdomyosarcomas. For 40% of patients, the sarcoma was their first cancer (Poumeaud et al., 2025).
The authors recommended testing these tumours for mismatch repair deficiency. This can reveal Lynch syndrome and point to a treatment option.
4. How does it look
On scans
| Test | Typical findings |
|---|---|
| MRI | Large, deep mass within muscle, often with areas of bleeding or dead tissue |
| CT of the chest | Looks for lung spread |
| PET-CT | Shows spread elsewhere |
| Ultrasound | First test for many lumps; not enough on its own |
In the Furlong series, tumours measured from 1.5 to 15 cm, with a median of about 7 cm.
Under the microscope
| Feature | Description |
|---|---|
| Cells | Large, bizarre, many-shaped cells with abundant pink cytoplasm (rhabdomyoblasts) |
| Background | Round or spindle-shaped tumour cells |
| Muscle markers | Desmin, myogenin (MYF4), MyoD1 and myoglobin |
| Grade | High grade |
| Mismatch repair proteins | Tested to look for Lynch syndrome |
Diagnosis requires the typical cells together with at least one skeletal muscle-specific marker (Furlong, Mentzel and Fanburg-Smith, 2001). Desmin was positive in nearly all cases in that study.
5. Symptoms
Common symptoms
- A lump or swelling, usually deep in the thigh, leg, arm or trunk
- A lump that grows over weeks or months
- Pain or tenderness, though some lumps are painless
Less common symptoms
| Symptom | Possible cause |
|---|---|
| Abdominal swelling or pain | Tumour in the abdomen or retroperitoneum |
| Scrotal lump | Tumour of the spermatic cord |
| Cough or breathlessness | Lung spread |
| Weight loss and tiredness | Advanced disease |
| Leg swelling | Pressure on veins or lymph channels |
When to seek medical advice
See a doctor about any lump that is larger than 5 cm, deep under the muscle covering, growing or painful. Ask for referral to a sarcoma service for scans and biopsy.
6. Diagnosis
| Test | Purpose |
|---|---|
| MRI of the lump | Size, depth and relation to nerves and vessels |
| Core needle biopsy | Planned with the sarcoma team, along the future surgical route |
| Immunostains | Confirm skeletal muscle differentiation |
| Mismatch repair testing | Identifies tumours that may respond to immunotherapy and suggests Lynch syndrome |
| CT of the chest | Staging for lung spread |
| PET-CT | Selected cases |
| Genetic counselling | If Lynch syndrome is suspected |
Staging
Staging uses the TNM system for soft tissue sarcoma, taking into account size, depth, grade, nodal spread and distant spread. PRMS is always high grade.
7. Treatment
There is no standard treatment specific to PRMS. Most specialists treat it like other high-grade adult soft tissue sarcomas (Noujaim et al., 2015). Treatment should be given in a specialist sarcoma centre.
Localised disease
| Treatment | Details |
|---|---|
| Wide surgical excision | Removes the tumour with a margin of healthy tissue; the cornerstone of treatment |
| Radiotherapy | Before or after surgery to reduce the risk of local recurrence |
| Chemotherapy | Sometimes considered for large, high-risk tumours in fit patients |
| Limb-sparing surgery | Usually possible; amputation is rarely needed |
What a treatment plan may look like
| Step | What happens | Typical timing |
|---|---|---|
| Diagnosis and staging | MRI, biopsy, chest CT, pathology review | 2-4 weeks |
| Radiotherapy before surgery | Daily weekday sessions | About 5 weeks |
| Rest period | Allows swelling to settle | 4-6 weeks |
| Surgery | Wide removal of the tumour | Hospital stay of several days |
| Rehabilitation | Physiotherapy and wound care | Weeks to months |
Some centres give radiotherapy after surgery instead; both approaches are used.
Advanced or metastatic disease
| Treatment | Notes |
|---|---|
| Doxorubicin, alone or with ifosfamide | Common first-line choices |
| Paediatric-style regimens | Used occasionally; benefit uncertain |
| Immune checkpoint inhibitors | Considered for mismatch repair-deficient tumours |
| Surgery or radiotherapy for lung spread | In selected patients with few metastases |
| Palliative radiotherapy | For pain or other symptoms |
| Clinical trials | Encouraged |
In a multicentre study of 45 patients, responses to chemotherapy were poor: one partial response and six cases of stable disease, with a median progression-free survival of just over two months (Noujaim et al., 2015).
By contrast, in the Lynch syndrome study, half of eight patients treated with immunotherapy responded, including three complete radiological responses (Poumeaud et al., 2025).
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Wound problems, loss of muscle function, swelling, nerve damage |
| Radiotherapy | Skin reactions, wound healing problems, stiffness, swelling |
| Doxorubicin | Tiredness, hair loss, infection risk, heart effects |
| Ifosfamide | Kidney and bladder effects, confusion |
| Immunotherapy | Inflammation of organs such as bowel, lungs, liver or thyroid |
Treatment in older or frail patients
Because PRMS often affects older people, treatment is tailored to fitness. Surgery and radiotherapy may still be possible, while intensive chemotherapy may be avoided. Single-agent drugs, symptom control and good supportive care are important options.
8. Outlook (prognosis)
| Study | Findings |
|---|---|
| Furlong et al. (2001), 30 patients with follow-up | 70% died of disease, at a mean of 20 months; 27% had no evidence of disease |
| Noujaim et al. (2015), 45 patients | Median survival 12.8 months for localised and 7.1 months for metastatic disease; relapse in 54% |
Factors affecting outlook
| Factor | Effect |
|---|---|
| Small tumour, completely removed | Better chance of long-term control |
| Spread at diagnosis | Poorer outlook |
| Older age and frailty | Limit treatment options |
| Mismatch repair deficiency | May open the option of immunotherapy |
These figures are sobering, but they are averages from small studies. Some people, particularly those with small tumours that are fully removed, remain free of disease for many years.
9. Follow-up
| Time | Typical checks |
|---|---|
| Years 1-2 | Clinic visit, MRI of the original site and chest CT every 3 months |
| Years 3-5 | Every 4-6 months |
| After 5 years | Yearly review |
| Lynch syndrome | Additional screening for bowel, womb and other cancers |
10. Living with pleomorphic rhabdomyosarcoma
- Ask to be treated in a specialist sarcoma centre
- Work with physiotherapists to regain strength and movement after surgery
- Report new lumps, cough or breathlessness promptly
- Ask whether your tumour was tested for mismatch repair deficiency
- Tell relatives if you are found to have Lynch syndrome, so they can be offered testing
- Discuss your goals and priorities with your team, particularly if the disease is advanced
- Seek support from sarcoma charities and palliative care teams when needed
Support and palliative care
Palliative care teams specialise in controlling symptoms such as pain, breathlessness and tiredness, and in supporting families. They can be involved at any stage, not only at the end of life, and work alongside cancer treatment. Many people find that early contact with these teams improves their quality of life.
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is it the same as childhood rhabdomyosarcoma? | No; it is a distinct adult tumour that behaves and responds differently |
| Will I lose my limb? | Usually not; limb-sparing surgery is possible in most cases |
| Why is chemotherapy less helpful? | This tumour often responds poorly to standard sarcoma drugs |
| Can immunotherapy help? | It may, especially if the tumour is mismatch repair-deficient |
| Is it inherited? | Usually not, but some cases occur in people with Lynch syndrome |
| Can it come back? | Yes; relapse is common, so regular scans are important |
| How long will treatment take? | Usually several months from diagnosis to the end of surgery and radiotherapy |
| Will I be able to walk normally? | Most people regain good function, though some have lasting weakness |
| Can I get a second opinion? | Yes; specialist sarcoma pathology review is recommended |
12. Questions to ask your care team
- Has the diagnosis been confirmed by a sarcoma pathologist?
- Has my tumour been tested for mismatch repair deficiency?
- Can the tumour be completely removed?
- Do I need radiotherapy before or after surgery?
- Would chemotherapy or immunotherapy help me?
- Are there clinical trials I could join?
- What follow-up will I have?
- Who can I contact for help with pain or other symptoms?
- Should my family be offered genetic testing?
Resources
- Furlong, M.A., Mentzel, T. and Fanburg-Smith, J.C. (2001) ‘Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers’, Modern Pathology, 14(6), pp. 595-603.
- Hollowood, K. and Fletcher, C.D. (1994) ‘Rhabdomyosarcoma in adults’, Seminars in Diagnostic Pathology, 11(1), pp. 47-57.
- Noujaim, J. et al. (2015) ‘Adult pleomorphic rhabdomyosarcoma: a multicentre retrospective study’, Anticancer Research, 35(11), pp. 6213-6217.
- Poumeaud, F. et al. (2025) ‘Sarcomas developed in patients with Lynch syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy’, European Journal of Cancer, 216, 115196.
- National Cancer Institute (2026) Adult Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.